An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Official Title

An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma


The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for Group 3. There is an equal chance to be assigned to either Group 1 or Group 2. Group 3 is no longer open for enrollment.

Trial Description

Primary Outcome:

  • Progression free survival (PFS) by Independent Review Committee (IRC)
Secondary Outcome:
  • Time to objective response (TTR)
  • Duration of objective response (DOR)
  • Investigator-assessed PFS
  • Investigator-assessed ORR
  • Objective response rate (ORR) by IRC
  • Overall Survival (OS)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society